Published in Proc Natl Acad Sci U S A on February 14, 2003
Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res (2010) 1.79
A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.54
Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed) (2012) 1.28
The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol (2009) 1.06
Complement factor h is critical in the maintenance of retinal perfusion. Am J Pathol (2009) 0.96
Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization. J Biol Chem (2011) 0.96
Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol (2010) 0.95
Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. BMC Cancer (2010) 0.95
Vascular targeting to the SST2 receptor improves the therapeutic response to near-IR two-photon activated PDT for deep-tissue cancer treatment. Biochim Biophys Acta (2013) 0.89
Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. Breast Cancer Res Treat (2010) 0.89
Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. Br J Cancer (2011) 0.87
Evidence for enhanced tissue factor expression in age-related macular degeneration. Lab Invest (2010) 0.86
IKK2 inhibition attenuates laser-induced choroidal neovascularization. PLoS One (2014) 0.85
Exosomes from retinal astrocytes contain antiangiogenic components that inhibit laser-induced choroidal neovascularization. J Biol Chem (2013) 0.84
Roles of NFκB-miR-29s-MMP-2 circuitry in experimental choroidal neovascularization. J Neuroinflammation (2014) 0.83
Inhibition of new vessel growth in mouse model of laser-induced choroidal neovascularization by adiponectin peptide II. Cell Biol Int (2009) 0.83
Inhibitory role of adiponectin peptide I on rat choroidal neovascularization. Biochim Biophys Acta (2012) 0.83
Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci (2015) 0.81
Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunol (2010) 0.81
The effects of small interfering RNA-targeting tissue factor on an in vitro model of neovascularization. Mol Vis (2013) 0.78
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy. Angiogenesis (2016) 0.77
Endometriosis, angiogenesis and tissue factor. Scientifica (Cairo) (2012) 0.76
The effect of nicotine on anti-vascular endothelial growth factor therapy in a mouse model of neovascular age-related macular degeneration. Retina (2012) 0.75
Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. Oncotarget (2016) 0.75
Tissue factor with age-related macular degeneration. Int J Ophthalmol (2012) 0.75
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 21.37
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol (1999) 8.92
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol (2001) 7.60
Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol (1989) 5.41
In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med (1996) 4.86
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol (1984) 4.68
Age-related macular degeneration. N Engl J Med (2000) 3.32
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results. Ophthalmology (1992) 2.33
Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol (1997) 2.01
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina (2002) 1.62
Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A (1999) 1.35
Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual outcomes. Retina (2001) 1.29
Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci (2000) 1.27
Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A (2001) 1.22
Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol (2002) 1.18
Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med (1999) 1.18
Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest (1997) 1.18
Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A (2000) 1.14
Transplantation of RPE in age-related macular degeneration: observations in disciform lesions and dry RPE atrophy. Graefes Arch Clin Exp Ophthalmol (1997) 1.10
Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci (2000) 1.07
Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proc Natl Acad Sci U S A (1999) 1.06
Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat Biotechnol (1999) 1.05
Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol (2002) 0.99
Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology (2008) 3.90
Severe chronic experimental autoimmune uveitis (EAU) of the C57BL/6 mouse induced by adoptive transfer of IRBP1-20-specific T cells. Exp Eye Res (2005) 1.95
Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol (2005) 1.89
Generation of an inbred miniature pig model of retinitis pigmentosa. Invest Ophthalmol Vis Sci (2012) 1.87
Adult retinal pigment epithelial transplantation in exudative age-related macular degeneration. Am J Ophthalmol (2007) 1.82
Role of human noncoding RNAs in the control of tumorigenesis. Proc Natl Acad Sci U S A (2009) 1.76
Age-related changes in human RPE cell density and apoptosis proportion in situ. Invest Ophthalmol Vis Sci (2002) 1.50
Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci (2007) 1.49
Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells. J Immunol (2009) 1.48
Roles of PSF protein and VL30 RNA in reversible gene regulation. Proc Natl Acad Sci U S A (2005) 1.43
Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol (2006) 1.42
Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med (2003) 1.38
The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol (2007) 1.37
Binding of mouse VL30 retrotransposon RNA to PSF protein induces genes repressed by PSF: effects on steroidogenesis and oncogenesis. Proc Natl Acad Sci U S A (2004) 1.35
Differentiation of induced pluripotent stem cells of swine into rod photoreceptors and their integration into the retina. Stem Cells (2011) 1.29
Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Invest Ophthalmol Vis Sci (2009) 1.29
Behavioral and anatomical abnormalities in a sodium iodate-induced model of retinal pigment epithelium degeneration. Exp Eye Res (2005) 1.29
Mouse gammadelta T cells are capable of expressing MHC class II molecules, and of functioning as antigen-presenting cells. J Neuroimmunol (2008) 1.25
Regulation of proto-oncogene transcription, cell proliferation, and tumorigenesis in mice by PSF protein and a VL30 noncoding RNA. Proc Natl Acad Sci U S A (2009) 1.23
Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol (2009) 1.23
Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse. Invest Ophthalmol Vis Sci (2004) 1.22
Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci (2010) 1.21
Decreased visual function after patchy loss of retinal pigment epithelium induced by low-dose sodium iodate. Invest Ophthalmol Vis Sci (2009) 1.20
Taz-tead1 links cell-cell contact to zeb1 expression, proliferation, and dedifferentiation in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2010) 1.19
Retroviral-mediated transmission of a mouse VL30 RNA to human melanoma cells promotes metastasis in an immunodeficient mouse model. Proc Natl Acad Sci U S A (2002) 1.15
The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol (2009) 1.06
Primary retinal detachment repair: comparison of 1-year outcomes of four surgical techniques. Retina (2011) 1.06
Uveitis referral pattern in a Midwest University Eye Center. Ocul Immunol Inflamm (2003) 1.05
Survival of allogeneic porcine retinal pigment epithelial sheets after subretinal transplantation. Invest Ophthalmol Vis Sci (2004) 1.05
Conversion of monophasic to recurrent autoimmune disease by autoreactive T cell subsets. J Immunol (2003) 1.05
Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells. Invest Ophthalmol Vis Sci (2006) 1.04
A shared epitope of the interphotoreceptor retinoid-binding protein recognized by the CD4+ and CD8+ autoreactive T cells. J Immunol (2005) 1.04
Encephalitogenic activity of truncated myelin oligodendrocyte glycoprotein (MOG) peptides and their recognition by CD8+ MOG-specific T cells on oligomeric MHC class I molecules. Int Immunol (2003) 1.02
Zeb1 mutant mice as a model of posterior corneal dystrophy. Invest Ophthalmol Vis Sci (2008) 1.02
Reengineering of aged Bruch's membrane to enhance retinal pigment epithelium repopulation. Invest Ophthalmol Vis Sci (2004) 1.00
Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU). J Immunol (2006) 1.00
Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology. Invest Ophthalmol Vis Sci (2009) 1.00
The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci (2006) 1.00
Regulatory effect of gammadelta T cells on IL-17+ uveitogenic T cells. Invest Ophthalmol Vis Sci (2010) 1.00
Novel role for a complement regulatory protein (CD46) in retinal pigment epithelial adhesion. Invest Ophthalmol Vis Sci (2003) 0.99
Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis. Invest Ophthalmol Vis Sci (2006) 0.99
Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice. J Immunol (2011) 0.99
Synthesis and secretion of hemoglobin by retinal pigment epithelium. Invest Ophthalmol Vis Sci (2008) 0.99
Role of CD25+ dendritic cells in the generation of Th17 autoreactive T cells in autoimmune experimental uveitis. J Immunol (2012) 0.98
Characterization of rat CD8+ uveitogenic T cells specific for interphotoreceptor retinal-binding protein 1177-1191. J Immunol (2004) 0.98
Expression of adiponectin in choroidal tissue and inhibition of laser induced choroidal neovascularization by adiponectin. FEBS Lett (2007) 0.97
Chronic recurrent autoimmune uveitis with progressive photoreceptor damage induced in rats by transfer of IRBP-specific T cells. J Neuroimmunol (2005) 0.97
Large dielectric constant and high thermal conductivity in poly(vinylidene fluoride)/barium titanate/silicon carbide three-phase nanocomposites. ACS Appl Mater Interfaces (2011) 0.97
Activated gammadelta T cells promote the activation of uveitogenic T cells and exacerbate EAU development. Invest Ophthalmol Vis Sci (2011) 0.97
IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis. J Immunol (2011) 0.96
Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization. J Biol Chem (2011) 0.96
Effect of physician reimbursement methodology on the rate and cost of cataract surgery. Arch Ophthalmol (2005) 0.96
In vitro activation of CD8 interphotoreceptor retinoid-binding protein-specific T cells requires not only antigenic stimulation but also exogenous growth factors. J Immunol (2006) 0.96
Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol (2010) 0.95
Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody. Ocul Immunol Inflamm (2007) 0.95
Suspected simultaneous bilateral anterior ischemic optic neuropathy in a patient with Behçet's disease. Ocul Immunol Inflamm (2005) 0.95
IL-23 receptor expression on γδ T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis. J Immunol (2013) 0.93
Minimally activated CD8 autoreactive T cells specific for IRBP express a high level of Foxp3 and are functionally suppressive. Invest Ophthalmol Vis Sci (2007) 0.93
Reactivation of uveitogenic T cells by retinal astrocytes derived from experimental autoimmune uveitis-prone B10RIII mice. Invest Ophthalmol Vis Sci (2008) 0.93
Extracellular matrix ligands promote RPE attachment to inner Bruch's membrane. Curr Eye Res (2002) 0.93
Type I collagen is the autoantigen in experimental autoimmune anterior uveitis. J Immunol (2004) 0.93
Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes. Invest Ophthalmol Vis Sci (2009) 0.93
Pathogenesis of age-related macular degeneration. Trends Mol Med (2004) 0.93
Endogenous bone marrow derived cells express retinal pigment epithelium cell markers and migrate to focal areas of RPE damage. Invest Ophthalmol Vis Sci (2007) 0.93
Retinal pigment epithelial cells activate uveitogenic T cells when they express high levels of MHC class II molecules, but inhibit T cell activation when they express restricted levels. J Neuroimmunol (2003) 0.92
Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci (2005) 0.92
Intraocular diseases - anterior uveitis. Chem Immunol Allergy (2007) 0.92
Enhanced induction of RPE lineage markers in pluripotent neural stem cells engrafted into the adult rat subretinal space. Invest Ophthalmol Vis Sci (2003) 0.92
Bruch's membrane aging decreases phagocytosis of outer segments by retinal pigment epithelium. Mol Vis (2007) 0.91
Systemically transferred hematopoietic stem cells home to the subretinal space and express RPE-65 in a mouse model of retinal pigment epithelium damage. Exp Eye Res (2006) 0.91
PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells. J Leukoc Biol (2010) 0.91
Comparison of electrically evoked cortical potential thresholds generated with subretinal or suprachoroidal placement of a microelectrode array in the rabbit. J Neural Eng (2005) 0.91
A new model of experimental autoimmune keratoconjunctivitis sicca (KCS) induced in Lewis rat by the autoantigen Klk1b22. Invest Ophthalmol Vis Sci (2008) 0.90
Direct observation of rotatable uncompensated spins in the exchange bias system Co/CoO-MgO. Nanoscale (2013) 0.90
Maculoplasty for age-related macular degeneration: reengineering Bruch's membrane and the human macula. Prog Retin Eye Res (2006) 0.90
Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells. Am J Pathol (2008) 0.90
Stem cells as tools in regenerative therapy for retinal degeneration. Arch Ophthalmol (2009) 0.89